March 8, 2017Open Access

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Almost 11 years of follow-up showed that the efficacy of imatinib persisted over time and that long-term administration of imatinib was not associated with unacceptable cumulative or late toxic effects. (Funded by Novartis Pharmaceuticals; IRIS ClinicalTrials.gov numbers, NCT00006343 and NCT00333840 .).

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Hochhaus et al. (Wed,) studied this question.

synapsesocial.com/papers/69deb3b740ea065679559288 https://doi.org/https://doi.org/10.1056/nejmoa1609324

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells2015 · 58 citations
2Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.2002 · 469 citations
3Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)2015 · 17 citations
4Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV2013 · 299 citations
5Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV2015 · 274 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo